Skip to Content
Merck
  • Isolation, expression and characterization of a novel dual serine protease inhibitor, OH-TCI, from king cobra venom.

Isolation, expression and characterization of a novel dual serine protease inhibitor, OH-TCI, from king cobra venom.

Peptides (2008-06-28)
Ying-Ying He, Shu-Bai Liu, Wen-Hui Lee, Jin-Qiao Qian, Yun Zhang
ABSTRACT

Snake venom Kunitz/BPTI members are good tools for understanding of structure-functional relationship between serine proteases and their inhibitors. A novel dual Kunitz/BPTI serine proteinase inhibitor named OH-TCI (trypsin- and chymotrypsin-dual inhibitor from Ophiophagus hannah) was isolated from king cobra venom by three chromatographic steps of gel filtration, trypsin affinity and reverse phase HPLC. OH-TCI is composed of 58 amino acid residues with a molecular mass of 6339Da. Successful expression of OH-TCI was performed as the maltose-binding fusion protein in E. coli DH5alpha. Much different from Oh11-1, the purified native and recombinant OH-TCI both had strong inhibitory activities against trypsin and chymotrypsin although the sequence identity (74.1%) between them is very high. The inhibitor constants (K(i)) of recombinant OH-TCI were 3.91 x 10(-7) and 8.46 x10(-8)M for trypsin and chymotrypsin, respectively. To our knowledge, it was the first report of Kunitz/BPTI serine proteinase inhibitor from snake venom that had equivalent trypsin and chymotrypsin inhibitory activities.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Quetiapine hemifumarate salt, ≥98% (HPLC)
Sigma-Aldrich
4-Nitrophenyl 4-guanidinobenzoate hydrochloride, protease inhibitor and substrate